Successful elimination of bilirubin in critically ill patients with acute liver dysfunction using a cytokine adsorber and albumin dialysis: a pilot study

Abstract There are different methods of artificial liver support for patients with acute liver dysfunction (ALD). However, CytoSorb (CS) might be a new approved option for those patients. Question of interest is whether the elimination performance of CS was comparable to that of advanced organ suppo...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Christina Scharf, Uwe Liebchen, Michael Paal, Andrea Becker-Pennrich, Michael Irlbeck, Michael Zoller, Ines Schroeder
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/5c4393c897be42d1b332b1f8ee39c661
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:5c4393c897be42d1b332b1f8ee39c661
record_format	dspace
spelling	oai:doaj.org-article:5c4393c897be42d1b332b1f8ee39c6612021-12-02T15:55:03ZSuccessful elimination of bilirubin in critically ill patients with acute liver dysfunction using a cytokine adsorber and albumin dialysis: a pilot study10.1038/s41598-021-89712-42045-2322https://doaj.org/article/5c4393c897be42d1b332b1f8ee39c6612021-05-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-89712-4https://doaj.org/toc/2045-2322Abstract There are different methods of artificial liver support for patients with acute liver dysfunction (ALD). However, CytoSorb (CS) might be a new approved option for those patients. Question of interest is whether the elimination performance of CS was comparable to that of advanced organ support (ADVOS). Patients, treated with CS (integrated into high-flux dialysis) or ADVOS and a total bilirubin > 10 mg/dl were included. Laboratory parameters were evaluated before starting therapy (d0) and 12–24 h thereafter (d1). The Wilcoxon-test with associated samples was used for statistical analysis. Thirty-nine patients (33 CS, 6 ADVOS) were included. The median bilirubin at d0 was 16.9 and 17.7 mg/dl and at d1 was 13.2 and 15.9 mg/dl, in the CS and ADVOS group, respectively. There was a significant bilirubin reduction as well in the CS group (p < 0.001, median relative reduction: 22.5%) as in the ADVOS group (p = 0.028, median relative reduction: 22.8%). There was no significant difference in the relative bilirubin reduction between CS and ADVOS therapies. The use of CytoSorb and ADVOS in patients with ALD led to a significant and comparable decrease in total bilirubin. The easy use of CS might be an advantage compared to other procedures.Christina ScharfUwe LiebchenMichael PaalAndrea Becker-PennrichMichael IrlbeckMichael ZollerInes SchroederNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-7 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Christina Scharf Uwe Liebchen Michael Paal Andrea Becker-Pennrich Michael Irlbeck Michael Zoller Ines Schroeder Successful elimination of bilirubin in critically ill patients with acute liver dysfunction using a cytokine adsorber and albumin dialysis: a pilot study
description	Abstract There are different methods of artificial liver support for patients with acute liver dysfunction (ALD). However, CytoSorb (CS) might be a new approved option for those patients. Question of interest is whether the elimination performance of CS was comparable to that of advanced organ support (ADVOS). Patients, treated with CS (integrated into high-flux dialysis) or ADVOS and a total bilirubin > 10 mg/dl were included. Laboratory parameters were evaluated before starting therapy (d0) and 12–24 h thereafter (d1). The Wilcoxon-test with associated samples was used for statistical analysis. Thirty-nine patients (33 CS, 6 ADVOS) were included. The median bilirubin at d0 was 16.9 and 17.7 mg/dl and at d1 was 13.2 and 15.9 mg/dl, in the CS and ADVOS group, respectively. There was a significant bilirubin reduction as well in the CS group (p < 0.001, median relative reduction: 22.5%) as in the ADVOS group (p = 0.028, median relative reduction: 22.8%). There was no significant difference in the relative bilirubin reduction between CS and ADVOS therapies. The use of CytoSorb and ADVOS in patients with ALD led to a significant and comparable decrease in total bilirubin. The easy use of CS might be an advantage compared to other procedures.
format	article
author	Christina Scharf Uwe Liebchen Michael Paal Andrea Becker-Pennrich Michael Irlbeck Michael Zoller Ines Schroeder
author_facet	Christina Scharf Uwe Liebchen Michael Paal Andrea Becker-Pennrich Michael Irlbeck Michael Zoller Ines Schroeder
author_sort	Christina Scharf
title	Successful elimination of bilirubin in critically ill patients with acute liver dysfunction using a cytokine adsorber and albumin dialysis: a pilot study
title_short	Successful elimination of bilirubin in critically ill patients with acute liver dysfunction using a cytokine adsorber and albumin dialysis: a pilot study
title_full	Successful elimination of bilirubin in critically ill patients with acute liver dysfunction using a cytokine adsorber and albumin dialysis: a pilot study
title_fullStr	Successful elimination of bilirubin in critically ill patients with acute liver dysfunction using a cytokine adsorber and albumin dialysis: a pilot study
title_full_unstemmed	Successful elimination of bilirubin in critically ill patients with acute liver dysfunction using a cytokine adsorber and albumin dialysis: a pilot study
title_sort	successful elimination of bilirubin in critically ill patients with acute liver dysfunction using a cytokine adsorber and albumin dialysis: a pilot study
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/5c4393c897be42d1b332b1f8ee39c661
work_keys_str_mv	AT christinascharf successfuleliminationofbilirubinincriticallyillpatientswithacuteliverdysfunctionusingacytokineadsorberandalbumindialysisapilotstudy AT uweliebchen successfuleliminationofbilirubinincriticallyillpatientswithacuteliverdysfunctionusingacytokineadsorberandalbumindialysisapilotstudy AT michaelpaal successfuleliminationofbilirubinincriticallyillpatientswithacuteliverdysfunctionusingacytokineadsorberandalbumindialysisapilotstudy AT andreabeckerpennrich successfuleliminationofbilirubinincriticallyillpatientswithacuteliverdysfunctionusingacytokineadsorberandalbumindialysisapilotstudy AT michaelirlbeck successfuleliminationofbilirubinincriticallyillpatientswithacuteliverdysfunctionusingacytokineadsorberandalbumindialysisapilotstudy AT michaelzoller successfuleliminationofbilirubinincriticallyillpatientswithacuteliverdysfunctionusingacytokineadsorberandalbumindialysisapilotstudy AT inesschroeder successfuleliminationofbilirubinincriticallyillpatientswithacuteliverdysfunctionusingacytokineadsorberandalbumindialysisapilotstudy
_version_	1718385450223140864

Successful elimination of bilirubin in critically ill patients with acute liver dysfunction using a cytokine adsorber and albumin dialysis: a pilot study

Ejemplares similares